[1. Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM 2007; 100:635.10.1093/qjmed/hcm07717846059]Search in Google Scholar
[2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.10.3322/caac.2013822237781]Search in Google Scholar
[3. Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127:299.10.1111/j.1365-2141.2004.05207.x15491289]Search in Google Scholar
[4. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.10.1182/blood-2010-05-28263220664057]Search in Google Scholar
[5. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.10.1038/bjc.2011.450324260722045184]Search in Google Scholar
[6. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.10.4065/78.1.2112528874]Search in Google Scholar
[7. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY, et al. Racial disparities in incidence and outcome in multiple myeloma: a population- based study. Blood 2010; 116:5501.10.1182/blood-2010-07-298760303140020823456]Search in Google Scholar
[8. Huang SY, Yao M, Tang JL, Lee WC, Tsay W, Cheng AL, et al. Epidemiology of multiple myeloma in Taiwan: increasing incidence for the past 25 years and higher prevalence of extramedullary myeloma in patients younger than 55 years. Cancer 2007; 110:896.10.1002/cncr.2285017594697]Search in Google Scholar
[9. Lynch HT, Sanger WG, Pirruccello S, Quinn-Laquer B, Weisenburger DD. Familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst 2001; 93(19):147910.1093/jnci/93.19.147911584064]Search in Google Scholar
[10. Winearls CG. Acute myeloma kidney. Kidney Int 1995; 48:1347.10.1038/ki.1995.4218569099]Search in Google Scholar
[11. Smith A, Wisloff F, Samson D; UK Myeloma Forum; Nordic Myeloma Study Group; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132:410.10.1111/j.1365-2141.2005.05867.x16412016]Search in Google Scholar
[12. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749.10.1046/j.1365-2141.2003.04355.x]Search in Google Scholar
[13. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001; 15:1274.10.1038/sj.leu.240218311480571]Search in Google Scholar
[14. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006; 81:693.10.4065/81.5.69316706268]Search in Google Scholar
[15. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158:1889.10.1001/archinte.158.17.18899759684]Search in Google Scholar
[16. Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, et al. Renal involvement in multiple myeloma: a 10- year study. Ren Fail 2000; 22:46510.1081/JDI-100100888]Search in Google Scholar
[17. http://www.uptodate.com/contents/types-of-renal-disease-in-multiple-myeloma]Search in Google Scholar
[18. Sanders PW. Mechanisms of Light Chain Injury along the Tubular Nephron. J Am Soc Nephrol 2012; 23(11):177710.1681/ASN.201204038822997259]Search in Google Scholar
[19. Dennen P, Parikh CR. Biomarkers of acute kidney injury: can we replace serum creatinine? Clin Nephrol 2007; 68(5):269.]Search in Google Scholar
[20. Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. J Am Soc Nephrol 2011; 22:810.10.1681/ASN.201008079621493774]Search in Google Scholar
[21. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61:1453.10.1046/j.1523-1755.2002.00253.x11918752]Search in Google Scholar
[22. Herget-Rosenthal S, Marggraf G, Hüsing J, Göring F, Pietruck F, Janssen O, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66:111510.1111/j.1523-1755.2004.00861.x15327406]Search in Google Scholar
[23. Edelstein CL, Faubel S. Biomarkers in acute kidney injury, in Edelstein CL. Biomarkers in Kidney Disease. Academic Press Elsevier 2011; pp.177-232.10.1016/B978-0-12-375672-5.10005-2]Search in Google Scholar
[24. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80:806.10.1038/ki.2011.19821697815]Search in Google Scholar
[25. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290:F517.10.1152/ajprenal.00291.200516174863]Search in Google Scholar
[26. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Devarajan P, et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 2008; 73:863.10.1038/sj.ki.5002715258690918059454]Search in Google Scholar
[27. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998; 13:1438.10.1093/ndt/13.6.14389641173]Search in Google Scholar
[28. Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 2012; 59:786.10.1053/j.ajkd.2011.12.02822417785]Search in Google Scholar
[29. Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89:630.10.1172/JCI1156294428961737851]Search in Google Scholar
[30. Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997; 99:732.10.1172/JCI1192185078579045877]Search in Google Scholar
[31. Decourt C, Rocca A, Bridoux F, Vrtovsnik F, Preud'homme JL, Cogné M, et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 1999; 94:3559.10.1182/blood.V94.10.3559.422k10_3559_3566]Search in Google Scholar
[32. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324:1845.10.1056/NEJM1991062732426031904132]Search in Google Scholar
[33. Pirani CL, Silva F, D'Agati V, Chander P, Striker LM. Renal lesions in plasma cell dyscrasias: ultrastructural observations. Am J Kidney Dis 1987; 10:20810.1016/S0272-6386(87)80176-2]Search in Google Scholar
[34. Ying WZ, Allen CE, Curtis LM, Aaron KJ, Sanders PW. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest 2012; 122:1777.10.1172/JCI46490333697122484815]Search in Google Scholar
[35. Magee C, Vella JP, Tormey WP, Walshe JJ. Multiple myeloma and renal failure: one center's experience. Ren Fail 1998; 20:597.10.3109/088602298090451529713878]Search in Google Scholar
[36. Weiss JH, Williams RH, Galla JH, Gottschall JL, Rees ED, Bhathena D, et al. Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney Int 1981; 20:19810.1038/ki.1981.1227289404]Search in Google Scholar
[37. Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC, et al. Myeloma light chains are ligands for cubilin (gp 280). Am J Physiol 1998; 275:F246.10.1152/ajprenal.1998.275.2.F2469691015]Search in Google Scholar
[38. Klassen RB, Allen PL, Batuman V, Crenshaw K, Hammond TG. Light chains are a ligand for megalin. J Appl Physiol 2005; 98:257.10.1152/japplphysiol.01090.200315286052]Search in Google Scholar
[39. Li M, Balamuthusamy S, Simon EE, Batuman V. Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells. Am J Physiol Renal 2008; 295:F82.10.1152/ajprenal.00091.200818448595]Search in Google Scholar
[40. Guan S, el-Dahr S, Dipp S, Batuman V. Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Investig Med 1999; 47:496.]Search in Google Scholar
[41. Diwakar R, Pearson AL, Colville-Nash P, Brunskill NJ, Dockrell ME. The role played by endocytosis in albumin- induced secretion of TGF-1 by proximal tubular epithelial cells. Am J Physiol Renal Physiol 2007; 292:F1464.10.1152/ajprenal.00069.200617213467]Search in Google Scholar
[42. Dreisbach AW, Batuman V. Low-molecular-weight protein competition for binding sites on renal brush border membranes. Ren Physiol Biochem 1994; 17:287.]Search in Google Scholar
[43. Verroust PJ, Christensen EI. Megalin and cubilin - the story of two multipurpose receptors unfolds. Nephrol Dial Transplant 2002; 17:1867.10.1093/ndt/17.11.186712401836]Search in Google Scholar
[44. Li M, Hering-Smith KS, Simon EE, Batuman V. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol Dial Transplant 2008; 23(3):860.10.1093/ndt/gfm67017933841]Search in Google Scholar
[45. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004; 104:40.10.1182/blood-2003-10-3400]Search in Google Scholar
[46. Lajoie G, Leung R, Bargman JM. Clinical, biochemical, and pathological features in a patient with plasma cell dyscrasia and Fanconi syndrome. Ultrastruct Pathol 2000; 24:221.10.1080/01913120050176671]Search in Google Scholar
[47. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126:348.10.1111/j.1365-2141.2004.05045.x]Search in Google Scholar
[48. Maldonado JE, Velosa JA, Kyle RA, Wagoner RD, Holley KE, Salassa RM. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med 1975; 58:354.10.1016/0002-9343(75)90601-4]Search in Google Scholar
[49. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108:2520 10.1182/blood-2006-03-00116416794250]Search in Google Scholar
[50. El Hamel C, Aldigier JC, Oblet C, Laffleur B, Bridoux F, Cogné M. Specific impairment of proximal tubular cell proliferation by a monoclonal κlight chain responsible for Fanconi syndrome. Nephrol Dial Transplant 2012; 27: 4368.10.1093/ndt/gfs26123024220]Search in Google Scholar
[51. Sanders PW, Herrera GA, Galla JH. Human Bence- Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int 1987; 32:851.10.1038/ki.1987.2863123760]Search in Google Scholar
[52. Batuman V. Proximal tubular injury in myeloma. Contrib Nephrol 2007; 153:87.10.1159/00009676217075225]Search in Google Scholar
[53. Wang PX, Sanders PW. Immunoglobulin light chains gene rate hydrogen peroxide. J Am Soc Nephrol 2007; 18:1239.10.1681/ASN.200611129917360948]Search in Google Scholar
[54. Basnayake K, Ying WZ, Wang PX, Sanders PW. Immunoglobulin light chains activate tubular epithelial cells through redox signaling. J Am Soc Nephrol 2010; 21:1165.10.1681/ASN.2009101089315223420558542]Search in Google Scholar
[55. Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW. Immunoglobulin light chains activate nuclear factor-kB in renal epithelial cells through a Src-dependent mechanism. Blood 2011; 117:1301.10.1182/blood-2010-08-302505305647321098396]Search in Google Scholar
[56. Ying WZ, Wang PX, Sanders PW. Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. Am J Pathol 2012; 180:41.10.1016/j.ajpath.2011.09.017333833822079929]Search in Google Scholar
[57. Sarközi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M, et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther 2008; 327(3):645.10.1124/jpet.108.14260418776064]Search in Google Scholar
[58. Barillé S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86:3151.10.1182/blood.V86.8.3151.3151]Search in Google Scholar
[59. Fattori E, Della Rocca C, Costa P, Giorgio M, Dente B, Pozzi L, et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 1994; 83:2570.10.1182/blood.V83.9.2570.2570]Search in Google Scholar
[60. Sengul S, Zwizinski C, Simon EE, Kapasi A, Singhal PC, Batuman V. Endocytosis of light chains induces cytokines through activation of NF-kappaB in human proximal tubule cells. Kidney Int 2002; 62:1977.10.1046/j.1523-1755.2002.00660.x12427122]Search in Google Scholar
[61. Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 2003; 284:F124510.1152/ajprenal.00350.200212582006]Search in Google Scholar
[62. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12:148210.1681/ASN.V127148211423577]Search in Google Scholar
[63. Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005; 11:8706 10.1158/1078-0432.CCR-05-048616361557]Search in Google Scholar